NCT05481736View on ClinicalTrials.gov

Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

November 18, 2024

Study Completion Date

November 18, 2024

Conditions
Anorexia Nervosa
Interventions
DRUG

Psilocybin

COMP360 Psilocybin administered under supportive conditions

Trial Locations (5)

21044

Sheppard Pratt Health System, Baltimore

78712

Dell Medical School, Austin

92037

Altman Clinical and Translational Research Institute, San Diego

Unknown

Tallaght University Hospital, Dublin

Kings College London, Institute of Psychiatry, Psychology and Neurology, London

Sponsors

Lead Sponsor

COMPASS Pathways
All Listed Sponsors
lead

COMPASS Pathways

INDUSTRY

NCT05481736 - Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study | Biotech Hunter | Biotech Hunter